1.
|
|
2.
|
11 p, 2.0 MB |
Enhancement of Antiviral CD8 + T-Cell Responses and Complete Remission of Metastatic Melanoma in an HIV-1-Infected Subject Treated with Pembrolizumab
/
Blanch-Lombarte, Oscar (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Gálvez, Cristina (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Revollo, Boris (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Jiménez-Moyano, Esther (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Llibre, Josep M.. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Manzano, José Luís (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Boada, Aram (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Dalmau, Judith (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
E. Speiser, Daniel (University of Lausanne, Switzerland) ;
Clotet Sala, Bonaventura (Universitat Autònoma de Barcelona. Departament de Medicina) ;
G. Prado, Julia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martínez Picado, Francisco Javier (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Background: Pembrolizumab is an immune checkpoint inhibitor against programmed cell death protein-1 (PD-1) approved for therapy in metastatic melanoma. PD-1 expression is associated with a diminished functionality in HIV-1 specific-CD8 + T cells. [...]
2019 - 10.3390/jcm8122089
Journal of clinical medicine, Vol. 8 (december 2019)
|
|
3.
|
17 p, 2.4 MB |
Tumor expression of cyclin-dependent kinase 5 (Cdk5) is a prognostic biomarker and predicts outcome of oxaliplatin-treated metastatic colorectal cancer patients
/
Ruiz de Porras, V. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Bystrup, Sara (Institut Germans Trias i Pujol) ;
Cabrero de las Heras, Sara (Institut Germans Trias i Pujol) ;
Musulén, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Palomero, L. (Institut d'Investigació Biomèdica de Bellvitge) ;
Alonso, M. H. (Universitat de Barcelona. Departament de Ciències Clíniques) ;
Nieto Raya, Rocio (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Arango, Diego (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Moreno, V. (Universitat de Barcelona. Departament de Ciències Clíniques) ;
Queralt, C. (Institut Germans Trias i Pujol) ;
Manzano Mozo, José Luís (Institut Germans Trias i Pujol) ;
Layos, Laura (Institut Germans Trias i Pujol) ;
Bugés, Cristina (Institut Germans Trias i Pujol) ;
Martínez Balibrea, Eva (Institut Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona
In recent years, an increasing number of studies have shown that elevated expression of cyclin dependent kinase (Cdk5) contributes to the oncogenic initiation and progression of many types of cancers. [...]
2019 - 10.3390/cancers11101540
Cancers, Vol. 11 Núm. 10 (october 2019) , p. 1540
|
|
4.
|
12 p, 744.6 KB |
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)
/
Carrato, Alfredo (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ;
Abad, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Massuti, Bartomeu (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Grávalos, Cristina (Hospital Universitario 12 de Octubre (Madrid)) ;
Escudero, Pilar (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Longo Muñoz, Federico (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ;
Manzano, José Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Gómez, Auxiliadora (Instituto Maimónides de Investigación Biomédica de Córdoba) ;
Safont, María José (Hospital General Universitario de Valencia) ;
Gallego, Javier (Hospital General Universitario de Elche) ;
García-Paredes, Beatriz (Hospital Clínico San Carlos (Madrid)) ;
Pericay, Carles (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Dueñas, Rosario (Complejo Hospitalario de Jaén) ;
Rivera, Fernando (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Losa, Ferrán (Hospital General de l'Hospitalet) ;
Valladares Ayerbes, Manuel (Complejo Hospitalario Universitario de A Coruña) ;
González, Encarnación (Hospital Universitario Virgen de las Nieves (Granada)) ;
Aranda Aguilar, Enrique (Instituto Maimónides de Investigación Biomédica de Córdoba) ;
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) ;
Universitat Autònoma de Barcelona
Abstract Background: In first-line wild-type (WT)-Kirsten rat sarcoma viral oncogene homologue (KRAS) metastatic colorectal cancer (mCRC), panitumumab (Pmab) improves outcomes when added to FOLFOX [folinic acid, 5-fluorouracil, and oxaliplatin] or FOLFIRI [folinic acid, 5-fluorouracil, and irinotecan]. [...]
2017 - 10.1016/j.ejca.2017.04.024
European journal of cancer, Núm. 81 (2017) , p. 191-202
|
|
5.
|
11 p, 912.9 KB |
Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice : a retrospective cross-sectional analysis
/
Capdevila Castillón, Jaume (Hospital Universitari Vall d'Hebron) ;
Sevilla, Isabel (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Alonso, Vicente (Hospital Universitario Miguel Servet (Saragossa)) ;
Antón Aparicio, Luís (Complejo Hospitalario Universitario de A Coruña) ;
Jiménez Fonseca, Paula (Hospital Universitario Central de Asturias) ;
Grande, Enrique (Hospital Universitario Ramón y Cajal (Madrid)) ;
Reina, Juan-José (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ;
Manzano, José Luís (Hospital Universitari Vall d'Hebron) ;
Alonso Lájara, Juan Domingo (Hospital Universitario Virgen de la Arrixaca (Múrcia)) ;
Barriuso, Jorge (Hospital Universitario La Paz (Madrid)) ;
Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ;
Medina, Javier (Complejo Hospitalario de Toledo) ;
López, Carlos (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Segura, Ángel (Hospital Universitari i Politècnic La Fe (València)) ;
Carrera, Sergio (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Crespo, Guillermo (Hospital Universitario de Burgos) ;
Fuster, Josep (Hospital Universitari Son Dureta (Palma de Mallorca, Balears)) ;
Munarriz, Javier (Consorci Hospitalari Provincial de Castelló) ;
García Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ;
Universitat Autònoma de Barcelona
Based on the mechanism of action, combining somatostatin analogues (SSAs) with mTOR inhibitors or antiangiogenic agents may provide synergistic effects for the treatment of patients with neuroendocrine tumours (NETs). [...]
2015 - 10.1186/s12885-015-1512-6
BMC Cancer, Vol. 15 (july 2015)
|
|
6.
|
17 p, 2.9 MB |
Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway
/
Ruiz de Porras, Vicenç (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Bystrup, Sara (Institut Germans Trias i Pujol) ;
Martínez Cardús, Anna (Institut d'Investigació Biomèdica de Bellvitge) ;
Pluvinet, Raquel (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ;
Sumoy, Lauro (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ;
Howells, Lynne (University of Leicester. Departament of Cancer Studies) ;
James, Mark I. (University of Leicester. Departament of Cancer Studies) ;
Iwuji, Chinenye (University of Leicester. Departament of Cancer Studies) ;
Manzano, José Luis (Institut Germans Trias i Pujol) ;
Layos, Laura (Institut Germans Trias i Pujol) ;
Bugés, Cristina (Institut Germans Trias i Pujol) ;
Abad, Albert (Hospital Cima Sanitas (Barcelona)) ;
Martínez Balibrea, Eva (Institut Germans Trias i Pujol)
Resistance to oxaliplatin (OXA) is a complex process affecting the outcomes of metastatic colorectal cancer (CRC) patients treated with this drug. De-regulation of the NF-κB signalling pathway has been proposed as an important mechanism involved in this phenomenon. [...]
2016 - 10.1038/srep24675
Scientific reports, Vol. 6 (April 2016)
|
|
7.
|
20 p, 10.3 MB |
PKM2 subcellular localization is involved in oxaliplatin resistance acquisition in HT29 human colorectal cancer cell lines
/
Ginés Molina, Alba (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Bystrup, Sara (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ruiz de Porras, Vicenç (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Guardia, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Musulén, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martínez Cardús, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Manzano, José Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Layos, Laura (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Abad, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martínez Balibrea, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Chemoresistance is the main cause of treatment failure in advanced colorectal cancer (CRC). However, molecular mechanisms underlying this phenomenon remain to be elucidated. In a previous work we identified low levels of PKM2 as a putative oxaliplatin-resistance marker in HT29 CRC cell lines and also in patients. [...]
2015 - 10.1371/journal.pone.0123830
PloS one, Vol. 10, No. 5 (May 2015) , p. e0123830
|
|